Class summary at a glance.

Every drug in the Biguanide (Antidiabetic) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $617.0Mcombined across class
Total Rx claims: 51.7M16.6M unique beneficiaries
Generic mfrs (active): 40across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Metformin

Brand: Glumetza · 51.7M Part D claims (CY24) · 16.6M beneficiaries · First FDA approval: 2002-01-24

40 generic mfrs 15 plans require PA

Low NADAC$0.014

→

Avg plan cost$0.390

Part D spend $617.0M 28× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.